tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRTX Stock Latest News

Vertex Pharmaceuticals’ Promising Kidney Franchise: Andrew Fein’s Buy Rating on Innovative Povetacicept and Strategic Expansion
RatingsVertex Pharmaceuticals’ Promising Kidney Franchise: Andrew Fein’s Buy Rating on Innovative Povetacicept and Strategic Expansion
8h ago
VRTX
Vertex Pharmaceuticals price target lowered to $563 from $565 at BofA
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $563 from $565 at BofA
8h ago
VRTX
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Reinforce Buy Rating
10h ago
VRTX
Vertex Pharmaceuticals announces updates across program for povetacicept
PremiumThe Fly
Vertex Pharmaceuticals announces updates across program for povetacicept
4d ago
VRTX
Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $438 from $439 at Morgan Stanley
11d ago
VRTX
Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline
PremiumRatingsVertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline
15d ago
VRTX
Vertex Pharmaceuticals price target raised to $575 from $550 at Citi
Premium
The Fly
Vertex Pharmaceuticals price target raised to $575 from $550 at Citi
19d ago
VRTX
Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
Premium
Ratings
Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
22d ago
VRTX
Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating
PremiumRatings
Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating
26d ago
VRTX
Morning Movers: CarMax slips following second quarter results
PremiumThe Fly
Morning Movers: CarMax slips following second quarter results
26d ago
C
C
Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept
PremiumThe Fly
Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept
26d ago
VRTX
Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial
PremiumThe Fly
Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial
26d ago
VRTX
Vertex Pharmaceuticals initiates AGLOW study of VX-407
PremiumThe FlyVertex Pharmaceuticals initiates AGLOW study of VX-407
26d ago
VRTX
Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth
Premium
The Fly
Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth
26d ago
VRTX
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
Premium
The Fly
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
26d ago
VRTX
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
27d ago
VRTX
Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
PremiumThe Fly
Vertex Pharmaceuticals announces CASGEVY reimbursement agreement in Italy
1M ago
VRTX
Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
PremiumRatings
Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
1M ago
VRTX
Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
PremiumRatings
Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
1M ago
VRTX
FDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics
PremiumRatingsFDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics
1M ago
VRTX
Vertex Pharmaceuticals: Promising Growth and Strategic Positioning Justify Buy Rating
Premium
Ratings
Vertex Pharmaceuticals: Promising Growth and Strategic Positioning Justify Buy Rating
1M ago
VRTX
Sionna Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Sionna Therapeutics initiated with a Strong Buy at Raymond James
2M ago
SION
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >